Ribon Therapeutics Encounters Extended Timeline
- Ribon Therapeutics, Inc.'s initial trial for their investigational PARP14 inhibitor, RBN-3143, is pushing expectations for its finish line. Originally set for April 30, 2023, it's now due by June 30, 2024.
- The research focuses on examining the safety and efficacy of the study drug in patients with Atopic Dermatitis.
- This delay might hint at potential challenges in recruitment, the performance of the research drug, or trial management, potentially increasing the risk of the company terminating the trial early.
- PARP14 inhibitors target a protein involved in DNA repair, potentially killing cancer cells by disrupting this process. They're still in early developmental stages but have shown preclinical potential against various tumors.
Other Research Endeavors by Ribon Therapeutics
- With programs spanning from Atopic Dermatitis to small cell lung cancer, Ribon showcases a strategy balancing deep commitment in one therapeutic area while exploring broader oncological footprints.
- The company is evaluating a Phase 2 trial of a PARP inhibitor, RBN-2397, in combination with pembrolizumab. This trial, focusing on patients with small cell lung cancer, is set for completion by November 1, 2023.
- They're also undergoing testing of another PARP inhibitor, RBN-2397, in patients battling advanced or metastatic solid tumors, expected to finish by June 30, 2023.
- PARP inhibitors, already approved for treating several cancers like ovarian, breast, pancreatic, and prostate, block the PARP enzyme, capitalizing on cancer cells' DNA repair defects.
Who's Playing on the Atopic Dermatitis Frontline?
- Ribon Therapeutics is navigating a crowded Atopic Dermatitis therapeutic space, indicating both the potential value of an effective treatment and the challenges of distinguishing oneself amidst giants like Pfizer and Eli Lilly.
- Eli Lilly and Company put lebrikizumab under the lens with results due by September 2024.
- Pfizer is examining PF-04965842 and Abrocitinib, aiming for a finish line in January 2026.
- Keymed Biosciences, in their Phase 2 trial, seeks to assess CM310 and is set for completion in October 2023.
- Amgen is scrutinizing Rocatinlimab, eyeing a new finish line in January 2025.
- Arcutis Biotherapeutics has their ARQ-151 cream undergoing testing, due to finish by October 2024.
- AbbVie, in their late-stage trials, is evaluating Upadacitinib, with a target end date of September 2023.
- Regeneron Pharmaceuticals is reviewing Dupilumab, aiming for results by August 2026.
- LEO Pharma, with their investigational compound Delgocitinib cream, eyes a completion by June 2024.
Sources: Clinicaltrials.gov, PubMed, Press Releases, and AppliedXL. This report is generated algorithmically and may not cover all ongoing industry-sponsored trials. AppliedXL implements rigorous AI vetting processes but cannot guarantee the completeness of all insights.